Average Co-Inventor Count = 7.73
ph-index = 10
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Astex Therapeutics Limited (13 from 123 patents)
2. Takeda Pharmaceutical Company Limited (2 from 1,177 patents)
3. Novartis Ag (1 from 3,923 patents)
4. The Institute of Cancer Research: Royal Cancer Hospital (1 from 51 patents)
5. Cancer Research Technology Limtied (1 from 1 patent)
15 patents:
1. 10519137 - Pyrazolyl quinoxaline kinase inhibitors
2. 10052320 - Substituted quinoxalines as FGFR kinase inhibitors
3. 10039759 - Quinolines as FGFR kinase modulators
4. 9994547 - Heteroarylamide inhibitors of TBK1
5. 9856236 - Substituted quinoxalines as FGFR kinase inhibitors
6. 9850228 - Pyrazolyl quinoxaline kinase inhibitors
7. 9598424 - Heteroarylamide inhibitors of TBK1
8. 9464071 - Pyrazolyl quinoxaline kinase inhibitors
9. 9439896 - Quinolines as FGFR kinase modulators
10. 9303029 - Substituted quinoxalines as FGFR kinase inhibitors
11. 9290478 - Substituted quinoxalines as FGFR kinase inhibitors
12. 8895601 - Pyrazolyl quinoxaline kinase inhibitors
13. 8796244 - Imidazopyridine derivatives as inhibitors of receptor tyrosine kinases
14. 8685980 - Pyrrolopyrimidine compounds and their uses
15. 8497294 - Compositions comprising (S)-2-amino-1-(4-chlorophenyl)-1-[4-(1H-pyrazol-4-yl)-phenyl]-ethanol as modulator of protein kinases